Cabaletta Bio (CABA) Interest Coverage Ratio (2024 - 2025)
Cabaletta Bio's quarterly Interest Coverage Ratio came in at 76.78 in Q4 2025, down 69.98% year-on-year from 255.78 in Q4 2024, and up 3.76% quarter-over-quarter from 79.77 in Q3 2025.
Cabaletta Bio has reported Interest Coverage Ratio for 2 years, with the latest figure at 76.78 in Q4 2025.
- For the quarter ending Q4 2025, Interest Coverage Ratio fell 69.98% year-over-year to 76.78; the trailing twelve-month figure through Dec 2025 stood at 85.95 (up 48.63% YoY), and the FY2025 full-year result was 85.95, up 48.63% from the prior year.
- Interest Coverage Ratio for Q4 2025 stood at 76.78, up from 79.77 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 45.17 in Q4 2024, with the low at 126.31 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | -76.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -76.78 |
| Sep 30, 2025 | -79.77 |
| Jun 30, 2025 | -80.40 |
| Mar 31, 2025 | -126.31 |
| Dec 31, 2024 | -45.17 |